Patient & Survivor Care
Conference Coverage
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUC
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic...
Conference Coverage
The sobering facts about alcohol and cancer
An ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise...
Conference Coverage
Chemo-immunotherapy good, adding a PARP inhibitor better in endometrial cancer?
Dr. Tan noted, the AtTEnd data "continue to validate practice-changing therapy for dMMR endometrial cancer patients."
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...
Conference Coverage
ICIs improve pCR rates in early ER+/HER2– breast cancer
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk...
Conference Coverage
Observation, not radiotherapy, after radical prostatectomy
The investigators observed no benefit to adjuvant radiotherapy after radical prostatectomy in patients with prostate cancer in the phase 3...
Conference Coverage
No benefit to adding ICI to chemo in triple-negative breast cancer: study
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without...
Conference Coverage
Remote symptom monitoring in advanced cancer improves quality of life
Building on prior studies, a new trial shows that digital symptom monitoring during cancer treatment detects symptoms early, improves quality of...
Conference Coverage
Fasting during breast cancer chemo improves quality of life
Short-term fasting around the time of chemotherapy is a promising supportive therapy during breast cancer chemotherapy that may enhance quality of...
Conference Coverage
Does first-line pembrolizumab add-on improve PFS in high-risk cervical cancer?
An FDA decision is expected in January on pembrolizumab with concurrent chemoradiotherapy for the first-line treatment of locally advanced...
Conference Coverage
Adjuvant abemaciclib-ET combo shows long-term benefit in high-risk early breast cancer
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy...